We have previously described the fact that deletion of the immunomodulatory VACV C6L gene, encoding an inhibitor of IFN-β [21,23], in the vector backbone of an MVA-based HIV/AIDS vaccine candidate induced the production of IFN-β and type I IFN inducible genes in infected innate immune cells and elicited an enhancement in the HIV-specific immunogenicity in immunized mice [22,24]. This evidence concerns the gene IFNB1 and AIDS.